← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	NSTG 26 DELISTED NanoString Technologies, Inc. NSTG	59	-9	-13%	$145M
27	27 DELISTED Adverum Biotechnologies ADVM	58	+58	–	$420M
28	28 Lineage Cell Therapeutics LCTX $243M	57	-5	-8%	$70.1M
29	29 Veracyte VCYT $3.64B	53	+3	+6%	$92.7M
30	30 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	52	-5	-9%	$43.7M
31	31 Arbutus Biopharma ABUS $842M	48	+9	+23%	$100M
32	ATHX 32 DELISTED Athersys, Inc. Common Stock ATHX	48	+2	+4%	$11.2M
33	AGTC 33 DELISTED Applied Genetic Technologies Corporation AGTC	42	+4	+11%	$104M
34	34 DELISTED Carisma Therapeutics CARM	42	+3	+8%	$130M
35	35 Fortress Biotech FBIO $64.7M	39	-9	-19%	$16.3M
36	36 Imunon IMNN $5.95M	34	-2	-6%	$8.44M
37	37 Opus Genetics IRD $333M	31	-4	-11%	$5.71M
38	38 Vericel Corp VCEL $2.11B	31	+5	+19%	$26M
39	39 ProQR Therapeutics PRQR $207M	30	+30	–	$130M
40	40 Pluri PLUR $12.1M	27	-1	-4%	$3.07M
41	41 uniQure QURE $1.5B	26	-1	-4%	$31.9M
42	42 CareDx CDNA $3.46B	22	+22	–	$36M
43	43 Fate Therapeutics FATE $230M	22	0	0%	$52.6M
44	44 Neurogene NGNE $478M	22	+3	+16%	$27.6M
45	45 DELISTED BioLife Solutions BLFS	15	+1	+7%	$1.22M
46	PTE 46 DELISTED PolarityTE, Inc. Common Stock PTE	13	-3	-19%	$311K
47	47 Enlivex Ltd ENLV $4.36M	8	+8	–	$9.47M
48	48 DELISTED BRAINSTORM CELL THERAPUTC BCLI	7	+7	–	$3.78M
49	49 Eterna Therapeutics ERNA $2.39M	7	0	0%	$6.1M
50	50 Qiagen QGEN $9.58B	1	+1	–	$478